2018 Q2 Form 10-Q Financial Statement
#000156459018018945 Filed on August 02, 2018
Income Statement
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| Revenue | $96.08M | $78.02M |
| YoY Change | 23.15% | 40.82% |
| Cost Of Revenue | $28.16M | $24.14M |
| YoY Change | 16.63% | 28.13% |
| Gross Profit | $67.92M | $53.87M |
| YoY Change | 26.08% | 47.36% |
| Gross Profit Margin | 70.69% | 69.05% |
| Selling, General & Admin | $64.70M | $54.27M |
| YoY Change | 19.21% | 58.18% |
| % of Gross Profit | 95.26% | 100.74% |
| Research & Development | $11.40M | $9.537M |
| YoY Change | 19.53% | 16.75% |
| % of Gross Profit | 16.78% | 17.7% |
| Depreciation & Amortization | $952.0K | $623.0K |
| YoY Change | 52.81% | 60.15% |
| % of Gross Profit | 1.4% | 1.16% |
| Operating Expenses | $76.12M | $63.81M |
| YoY Change | 19.29% | 50.21% |
| Operating Profit | -$8.201M | -$9.938M |
| YoY Change | -17.48% | 67.79% |
| Interest Expense | $2.579M | $2.454M |
| YoY Change | 5.09% | 152.47% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$592.0K | $416.0K |
| YoY Change | -242.31% | -163.71% |
| Pretax Income | -$10.24M | -$11.23M |
| YoY Change | -8.83% | 31.78% |
| Income Tax | $383.0K | $381.0K |
| % Of Pretax Income | ||
| Net Earnings | -$10.62M | -$11.61M |
| YoY Change | -8.53% | 32.25% |
| Net Earnings / Revenue | -11.05% | -14.88% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$353.3K | -$394.6K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 30.03M | 29.35M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $263.9M | $263.3M |
| YoY Change | 0.23% | -9.36% |
| Cash & Equivalents | $41.64M | $25.68M |
| Short-Term Investments | $223.0M | $238.4M |
| Other Short-Term Assets | $6.800M | $6.400M |
| YoY Change | 6.25% | -8.57% |
| Inventory | $95.00M | $87.00M |
| Prepaid Expenses | ||
| Receivables | $66.00M | $53.60M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $431.6M | $410.3M |
| YoY Change | 5.19% | 1.94% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $13.60M | $7.200M |
| YoY Change | 88.89% | 7.46% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $4.600M | $3.300M |
| YoY Change | 39.39% | 6.45% |
| Total Long-Term Assets | $18.30M | $10.50M |
| YoY Change | 74.29% | 7.14% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $431.6M | $410.3M |
| Total Long-Term Assets | $18.30M | $10.50M |
| Total Assets | $449.9M | $420.8M |
| YoY Change | 6.92% | 2.06% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $23.50M | $11.00M |
| YoY Change | 113.64% | -16.03% |
| Accrued Expenses | $27.90M | $24.00M |
| YoY Change | 16.25% | 57.89% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $53.50M | $37.05M |
| YoY Change | 44.38% | 21.09% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $148.6M | $141.5M |
| YoY Change | 5.0% | 4.99% |
| Other Long-Term Liabilities | $2.100M | $1.408M |
| YoY Change | 49.15% | 134.67% |
| Total Long-Term Liabilities | $150.7M | $142.9M |
| YoY Change | 5.44% | 5.56% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $53.50M | $37.05M |
| Total Long-Term Liabilities | $150.7M | $142.9M |
| Total Liabilities | $204.3M | $180.0M |
| YoY Change | 13.51% | 8.49% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$247.3M | |
| YoY Change | ||
| Common Stock | $488.9M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $245.6M | $240.8M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $449.9M | $420.8M |
| YoY Change | 6.92% | 2.05% |
Cashflow Statement
| Concept | 2018 Q2 | 2017 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$10.62M | -$11.61M |
| YoY Change | -8.53% | 32.25% |
| Depreciation, Depletion And Amortization | $952.0K | $623.0K |
| YoY Change | 52.81% | 60.15% |
| Cash From Operating Activities | $1.130M | -$3.480M |
| YoY Change | -132.47% | -67.35% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$1.440M | -$1.050M |
| YoY Change | 37.14% | 54.41% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $9.410M | $6.630M |
| YoY Change | 41.93% | -105.31% |
| Cash From Investing Activities | $7.980M | $5.590M |
| YoY Change | 42.75% | -104.45% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 4.310M | 3.410M |
| YoY Change | 26.39% | -97.54% |
| NET CHANGE | ||
| Cash From Operating Activities | 1.130M | -3.480M |
| Cash From Investing Activities | 7.980M | 5.590M |
| Cash From Financing Activities | 4.310M | 3.410M |
| Net Change In Cash | 13.42M | 5.520M |
| YoY Change | 143.12% | 140.0% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $1.130M | -$3.480M |
| Capital Expenditures | -$1.440M | -$1.050M |
| Free Cash Flow | $2.570M | -$2.430M |
| YoY Change | -205.76% | -75.65% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
383000 | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10620000 | |
| CY2018Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
96080000 | |
| CY2017Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
78016000 | |
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
183715000 | ||
| us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
146455000 | ||
| CY2018Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
28159000 | |
| CY2017Q2 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
24143000 | |
| CY2018Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-10237000 | |
| CY2018Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
273000 | |
| CY2018Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-45000 | |
| CY2018Q2 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-318000 | |
| CY2018Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10665000 | |
| us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
5993000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
104500000 | ||
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
133745000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6457000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1757000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-2844000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-5033000 | ||
| CY2018Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.35 | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
30028985 | |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1767000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
17564000 | ||
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
242000 | ||
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
-325000 | ||
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
400000 | ||
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
346000 | ||
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
3386000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
3628000 | ||
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
3380000 | ||
| nvro |
Unrealized Gains And Losses On Foreign Currency Translation
UnrealizedGainsAndLossesOnForeignCurrencyTranslation
|
-891000 | ||
| nvro |
Unrealized Gains And Losses On Foreign Currency Translation
UnrealizedGainsAndLossesOnForeignCurrencyTranslation
|
1290000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-2609000 | ||
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
470000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-2682000 | ||
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
4232000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
876000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
493000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
580000 | ||
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
136000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
4837000 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-4986000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-9341000 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-356000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
261000 | ||
| us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
197000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-5112000 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17246000 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
100887000 | ||
| us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
143014000 | ||
| CY2018Q2 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
850000 | |
| CY2017Q2 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
628000 | |
| CY2018Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
231539000 | |
| CY2018Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
42096000 | |
| CY2018Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
52898000 | |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
20246000 | |
| CY2018Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
6636000 | |
| CY2018Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
952000 | |
| CY2018Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
18447000 | |
| CY2018Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
4229000 | |
| CY2018Q2 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
1970000 | |
| CY2018Q2 | nvro |
Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
|
740000 | |
| CY2018Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
243000 | |
| CY2018Q2 | us-gaap |
Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
|
943000 | |
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
942000 | ||
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
655000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
6986000 | ||
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
43651000 | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5517000 | ||
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
6172000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6044000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-95000 | ||
| us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
225000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2007000 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-16537000 | ||
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
42212000 | |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
41644000 | |
| CY2017Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
25675000 | |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
695000 | ||
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
123000 | ||
| nvro |
Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
|
7000 | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant accounting estimates and management judgments reflected in the condensed consolidated financial statements include items such as allowances for doubtful accounts; warranty obligations; clinical accruals; stock-based compensation; depreciation and amortization periods; inventory valuation; valuation of investments; and accounting for income taxes. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by the management. Actual results may differ from those estimates under different assumptions or conditions.</p></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and investments. The majority of the Company’s cash is held by one financial institution in the United States and is in excess of federally insured limits. The Company maintained investments in money market funds that were not federally insured during the periods ended June 30, 2018 and December 31, 2017. The Company also held cash in foreign banks of approximately $5.6 million at June 30, 2018 and $4.5 million at December 31, 2017 that was not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s convertible note hedge transactions, entered into in connection with the 2021 Notes, subject the Company to credit risk such that the counterparties may be unable to fulfill the terms of the transactions. The associated risk is mitigated by limiting the counterparties to major financial institutions.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the international markets in which the Company participates, the Company uses a combination of a direct sales force, sales agents and independent distributors to sell its products, while in the United States the Company utilizes a direct sales force. The Company performs ongoing credit evaluations of its direct customers and distributors, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June 30, 2018 and 2017, no single customer accounted for 10% or more of the Company’s revenue. As of June 30, 2018 and December 31, 2017, no single customer accounted for 10% or more of the accounts receivable balance.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to medical device companies, including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, manufacturing quality and scaling, continued reimbursement from third-party payors,<font style="color:#1F497D;"> </font>uncertainty of market acceptance of products and the need to obtain additional financing. The Company is dependent on third-party manufacturers and suppliers, which, in some cases, are sole- or single-source suppliers.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that the Company’s products or services will continue to be accepted in its existing marketplaces, nor can there be any assurance that any future products or services can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products or services will be successfully marketed, if at all.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may choose to raise additional funds to further enhance its research and development efforts, for product expansion opportunities or to acquire a new business or products that are complementary to its business. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.</p></div> | ||
| CY2017Q1 | us-gaap |
Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
|
628000 | |
| CY2016Q4 | us-gaap |
Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
|
645000 | |
| CY2018Q2 | us-gaap |
Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
|
584000 | |
| CY2017Q2 | us-gaap |
Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
|
326000 | |
| us-gaap |
Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
|
1084000 | ||
| us-gaap |
Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
|
593000 | ||
| CY2018Q2 | us-gaap |
Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
|
461000 | |
| CY2017Q2 | us-gaap |
Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
|
298000 | |
| us-gaap |
Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
|
849000 | ||
| us-gaap |
Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
|
582000 | ||
| CY2017Q2 | us-gaap |
Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
|
656000 | |
| CY2018Q2 | us-gaap |
Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
|
0 | |
| CY2017Q4 | us-gaap |
Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
|
0 | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
30028985 | |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
29351537 | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
29933164 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
29256602 | ||
| CY2017Q2 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
123 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6812402 | ||
| CY2018Q2 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
600000 | |
| us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
2100000 | ||
| CY2017Q2 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
600000 | |
| us-gaap |
Standard Product Warranty Description
StandardProductWarrantyDescription
|
Limited one- to five-year warranty | ||
| us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | ||
| CY2017Q2 | us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | |
| nvro |
Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
|
P6M | ||
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-36700000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-14300000 | |
| us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
| CY2018Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-413000 | |
| CY2017Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
465000 | |
| CY2018Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-128000 | |
| CY2017Q2 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-3000 | |
| CY2018Q2 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
5600000 | |
| CY2017Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
4500000 | |
| CY2018Q2 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
13700000 | |
| CY2017Q4 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
30300000 | |
| CY2018Q2 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
500000 | |
| CY2017Q2 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
1300000 | |
| us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation
|
The Company recognizes revenue upon the transfer of control of the product and, for the majority of sales, there are no material future performance obligations beyond such transfer. As a result, the Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed. The Company does not capitalize incremental costs when the amortization period of the asset is less than a year. | ||
| CY2018Q2 | us-gaap |
Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
|
0 | |
| us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | ||
| CY2018Q2 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P1Y | |
| CY2018Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
235474000 | |
| CY2018Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | |
| CY2018Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
491000 | |
| CY2018Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
234985000 | |
| CY2017Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
226879000 | |
| CY2017Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | |
| CY2017Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
413000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
226467000 | |
| CY2018Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
232025000 | |
| CY2018Q2 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
3449000 | |
| CY2018Q2 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
3446000 | |
| CY2017Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
51602000 | |
| CY2017Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
46517000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
13688000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4869000 | |
| CY2017Q2 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
623000 | |
| CY2017Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
26108000 | |
| CY2017Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
4734000 | |
| CY2017Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
2827000 | |
| CY2017Q4 | nvro |
Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
|
1279000 | |
| CY2017Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
243000 | |
| CY2017Q4 | us-gaap |
Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
|
708000 | |
| CY2018Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3320000 | |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3491000 | |
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1504000 | ||
| us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
1211000 | ||
| CY2018Q1 | us-gaap |
Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
|
820000 | |
| us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
612 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6649591 | ||
| us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
1600000 |
